Expanding initiative focused on next generation sequencing services tailored to research needs
CORALVILLE, Iowa (July 15, 2021)
— Integrated DNA Technologies, Inc. (IDT)
, a leading comprehensive genomics research solutions provider, has added Predicine to the IDT Align Program. This move expands the program’s roster of preferred sequencing providers. The combination of IDT’s high quality and flexible next generation sequencing (NGS) products and Predicine’s cancer genomic and profiling services provides valuable solutions to support research projects.
The IDT Align Program was established to broaden access to services and solutions that help move genomic research projects forward. IDT is teaming with quality partners to make NGS tools and resources more accessible, especially for researchers who need custom research products and services.
Predicine is a California-based molecular insights company that has developed an NGS liquid biopsy platform to analyze cfDNA and cfRNA genomic alterations in blood and urine for research. Predicine’s 152-gene PredicineCARE™, 600-gene PredicineATLAS™, and PredicineALERT™ MRD liquid biopsy tests identify cancer variants (TMB, MSI, HRD, and gene deletion) as facilitate research into drug efficacy and minimal residual disease (MRD). Partnering with leading biopharmas, Predicine provides harmonized liquid biopsy tests and CDx development to support global clinical trials in the U.S., Europe, and the Asia-Pacific region, including China.
“IDT is excited to partner with Predicine and welcome them to the Align Program,” said IDT President Trey Martin. “Combining the technologies and expertise of IDT and Predicine will enable valuable tools to support the advancement of cancer genomics and profiling. Together we will empower researchers to reveal and understand underlying biology while discovering and exploring novel signatures.”
“We are excited to partner with IDT to expand our impact in cancer research with Predicine's liquid- and tissue-based genomic solutions for oncology and drug development research” said Dr. Shidong Jia, Founder and CEO of Predicine.
IDT is a leader in DNA writing and delivers innovative and high-performing NGS products to enable research and discoveries. NGS solutions from IDT feature high reproducibility, customization, and scalability that break down barriers for scientists who demand confidence in their results.
Predicine has a CAP-accredited and CLIA-certified laboratory in Hayward, California that uses cutting-edge technologies and instruments including the Illumina MiniSeq™, Illumina NextSeq™, and Illumina NovaSeq™ 6000 systems. Their high-caliber laboratory staff bring a wealth of sequencing and sample expertise to ensure accuracy and reliability of results.
For more information, visit www.idtdna.com
on Twitter for real-time updates and insights.
Integrated DNA Technologies, Inc. (IDT)
develops, manufactures, and markets nucleic acid products for the life sciences industry in the areas of academic and commercial research, agriculture, medical diagnostics, and pharmaceutical development. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, synthetic biology, digital PCR, and RNA interference. Through its GMP services, IDT manufactures products used by scientists researching many forms of cancer and most inherited and infectious diseases. IDT is widely recognized as the industry leader in custom nucleic acid manufacture, serving over 130,000 life sciences researchers. IDT was founded in 1987 and has its manufacturing headquarters in Coralville, Iowa, USA, with additional manufacturing sites in San Diego, California, USA; Research Triangle Park, North Carolina, USA; Leuven, Belgium; and Singapore. For more information, please visit www.idtdna.com
IDT Public Relations
800-328-2661 (USA & Canada)
+1 319-626-8400 (outside USA)
Predicine is a molecular insight company developing genomic profiling tests and robust algorithms for cancer research. Their biology-oriented approach to analyzing genomics is advancing the understanding of the tumor mutational landscape. For more information, follow Predicine on LinkedIn
and Twitter, or visit https://www.predicine.com